Background: Nirsevimab reduced both RSV LRTI and hospitalization: absolute risk reduction (ARR) 6.9% (95% CI, 4.1%–9.7%), number needed to treat (NNT) 14.5 (95% CI, 10.3–24.3) and ARR 3.3% (95% CI, 1.4%–5.2%), NNT 30.3 (95% CI, 19.4–69.5), respectively. These results were consistent throughout the RSV season following a single nirsevimab dose.

Author List: Madhi SA, Simões EAF.

Journal Name: J Pediatr. 2021 Jan;22 8:310-313. doi: 10.1016/j.jpeds.2020.10.066. PMID: 33342497.